Skip to main content
Equibles
RNXT logo

RNXT · RenovoRx, Inc.

Track RNXT — free

Use RNXT with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about RNXT

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.20 -0.20 (-14.29%)
Market Cap
$63.18M
Shares
45.13M

RenovoRx, Inc. Earnings Call Transcripts

Every quarterly earnings call for RenovoRx, Inc. (RNXT) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $197,000 −$2.42M '25 Q1 25-05-15 · $422,000 −$2.90M '25 Q2 25-08-14 · $266,000 −$2.91M '25 Q3 25-11-13 · $238,000 −$2.94M '25 Q4 26-03-30 ▲185.8% $563,000 −$3.52M '26 Q1 26-05-14 LATEST ▲115.4% $909,000 −$2.91M '26 Q2 26-08-12
Earnings call
FY26 · Q2
2026-08-12
Second Quarter 2026 Financial Results Conference Call
Confident tone TigerPAC Phase III trial progress Expansion beyond pancreatic cancer Record quarterly revenue growth
Revenue
$909,000
▲ 115.4% YoY
Diluted EPS
$-0.06
Gross margin
84.3%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-23
iAccess Alpha Virtual Best Ideas Summer Investement Conference 2026
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-14
RenovoRx, Inc. Q1 FY2026 Earnings Call
Confident tone Revenue growth and commercial momentum TIGeR-PaC Phase III trial progress RenovoCath / TAMP therapy platform
Revenue
$563,000
▲ 185.8% YoY
Diluted EPS
$-0.09
Gross margin
85.1%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-30
RenovoRx, Inc. Q4 FY2025 Earnings Call
Confident tone Revenue ramp and trajectory Commercial site expansion and pipeline TAMP / RenovoCath platform adoption
Revenue
$238,000*
Gross margin
88.2%
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-13
RenovoRx, Inc. Q3 FY2025 Earnings Call
Confident tone TIGER PACT Phase III trial Commercial adoption of RenovoCath TAMP therapy platform
Revenue
$266,000
Diluted EPS
$-0.08
Gross margin
80.1%
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
RenovoRx, Inc. Q2 FY2025 Earnings Call
Confident tone RenovoCath commercial launch and revenue Phase III TIGR PACT trial progress DMC interim analysis recommendation
Revenue
$422,000
Diluted EPS
$-0.08
Gross margin
64.0%
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
RenovoRx, Inc. Q1 FY2025 Earnings Call
Confident tone RenovoCath commercial launch and revenue Phase 3 TIGeR-PaC clinical trial progress TAMP therapy platform and IP
Revenue
$197,000
Diluted EPS
$-0.08
Gross margin
52.3%
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-30
RenovoRx, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–8 of 8 earnings calls
Key facts CIK 1574094 CUSIP 75989R107 13F (30d) 27 filings 27 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)